Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091737
Filing Date
2024-08-06
Accepted
2024-08-06 16:02:18
Documents
62
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nmra-20240630.htm   iXBRL 10-Q 2509304
2 EX-10.1 nmra-ex10_1.htm EX-10.1 20117
3 EX-31.1 nmra-ex31_1.htm EX-31.1 16979
4 EX-31.2 nmra-ex31_2.htm EX-31.2 16972
5 EX-32.1 nmra-ex32_1.htm EX-32.1 9971
6 EX-32.2 nmra-ex32_2.htm EX-32.2 9931
7 GRAPHIC img235849378_0.jpg GRAPHIC 100787
8 GRAPHIC img235849378_1.jpg GRAPHIC 16758
  Complete submission text file 0000950170-24-091737.txt   9216496

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20240630.xsd EX-101.SCH 1183389
65 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20240630_htm.xml XML 1466729
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41802 | Film No.: 241179008
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)